Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rectal Neoplasms × Sodium Chloride × Clear all

Phase

Phase NA 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 8 Lung Neoplasms 5 Colorectal Neoplasms 3 Prostatic Neoplasms 2 Neoplasm Metastasis 2 Melanoma 2 Hot Flashes 2 Glioblastoma 2 Carcinoma, Non-Small-Cell Lung 2 Surgical Wound 1 Squamous Cell Carcinoma of Head and Neck 1 Skin Neoplasms 1 Rectal Neoplasms 1 Pathologic Complete Response 1 Neoplasm, Residual 1 Lymphopenia 1 Lymphoma, Non-Hodgkin 1 Lymphedema 1 Lower Urinary Tract Symptoms 1 Locally Advanced Head and Neck Squamous Cell Carcinoma 1 Leukemia, Myeloid, Acute 1 Leukemia, Hairy Cell 1 Hematologic Neoplasms 1 Heart Failure 1 Glioma 1 Gastrointestinal Neoplasms 1 Fatigue 1 Esophageal Neoplasms 1 Ectropion 1 Dupuytren Contracture 1

Interventions

Oxaliplatin 129 Fluorouracil 119 Capecitabine 102 Leucovorin 94 Irinotecan 74 Radiotherapy 60 Bevacizumab 56 Cetuximab 39 Folfox protocol 25 Surgical Procedures, Operative 22 Drug Therapy 20 Radiation 18 Panitumumab 17 XELOX 16 Chemotherapy, Adjuvant 15 Neoadjuvant Therapy 14 Chemoradiotherapy 12 Radiotherapy, Intensity-Modulated 11 Floxuridine 9 regorafenib 8 Nivolumab 8 raltitrexed 7 IFL protocol 7 Celecoxib 7 trifluridine tipiracil drug combination 6 aflibercept 6 Trastuzumab 6 Melphalan 6 Immunohistochemistry 6 tislelizumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02682485 2023-04-26

SES-DTA

University of Chicago

Phase 2 Withdrawn

Gastrointestinal

Rectal Neoplasms, Anastomotic Leak

Data powered by HemOnc (CC BY 4.0) Colophon ⚡